ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer

Koichi Azuma, Makoto Nishio, Hidetoshi Hayashi, Katsuyuki Kiura, Miyako Satouchi, Shunichi Sugawara, Toyoaki Hida, Yasuo Iwamoto, Akira Inoue, Koji Takeda, Satoshi Ikeda, Tomoki Nakagawa, Kentaro Takeda, Seitaro Asahina, Kanji Komatsu, Satoshi Morita, Masahiro Fukuoka, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of East Asian patients with non-small-cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitors (TKIs). ASP8273 is an irreversible EGFR-TKI, given orally, that inhibits EGFR activating mutations and has shown clinical activity in patients with EGFR mutation-positive NSCLC. Epidermal growth factor receptor-TKI-naïve Japanese adult patients (≥20 years) with NSCLC harboring EGFR mutations were enrolled in this open-label, single-arm, phase II study (ClinicalTrials.gov identifier NCT02500927). Patients received ASP8273 300 mg once daily until discontinuation criteria were met. The primary end-point was to determine the safety of ASP8273 300 mg; the secondary end-point was antitumor activity defined by RECIST version 1.1. Thirty-one patients (12 men and 19 women; median age, 64 years [range, 31-82 years]) with EGFR mutation-positive NSCLC were enrolled; as of 23 February 2016, 25 patients (81%) were still on study. Of the 31 patients, 27 (87%) had an exon 19 deletion (n = 13, 42%) or an L858R (n = 14, 45%) EGFR activating mutation, and two (7%) had an L861Q mutation. Five patients (16%) had other EGFR activating mutations, two had an activating mutation and the T790M resistance mutation. The most commonly reported treatment-emergent adverse event was diarrhea (n = 24, 77%). All patients had at least one post-baseline scan; one patient (3%) achieved a confirmed complete response, 13 (42%) had a confirmed partial response, and 15 (48%) had confirmed stable disease (disease control rate, 94% [n = 29/31]) per investigator assessment. Once-daily ASP8273 at 300 mg was generally well tolerated and showed antitumor activity in TKI-naïve Japanese patients with EGFR mutation-positive NSCLC.

Original languageEnglish
Pages (from-to)2532-2538
Number of pages7
JournalCancer Science
Volume109
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Exons
Diarrhea
Research Personnel
Safety

Keywords

  • clinical trial
  • epidermal growth factor receptor
  • non-small-cell carcinoma
  • signal transduction inhibitors/kinase inhibitor
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. / Azuma, Koichi; Nishio, Makoto; Hayashi, Hidetoshi; Kiura, Katsuyuki; Satouchi, Miyako; Sugawara, Shunichi; Hida, Toyoaki; Iwamoto, Yasuo; Inoue, Akira; Takeda, Koji; Ikeda, Satoshi; Nakagawa, Tomoki; Takeda, Kentaro; Asahina, Seitaro; Komatsu, Kanji; Morita, Satoshi; Fukuoka, Masahiro; Nakagawa, Kazuhiko.

In: Cancer Science, Vol. 109, No. 8, 01.08.2018, p. 2532-2538.

Research output: Contribution to journalArticle

Azuma, K, Nishio, M, Hayashi, H, Kiura, K, Satouchi, M, Sugawara, S, Hida, T, Iwamoto, Y, Inoue, A, Takeda, K, Ikeda, S, Nakagawa, T, Takeda, K, Asahina, S, Komatsu, K, Morita, S, Fukuoka, M & Nakagawa, K 2018, 'ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer', Cancer Science, vol. 109, no. 8, pp. 2532-2538. https://doi.org/10.1111/cas.13651
Azuma, Koichi ; Nishio, Makoto ; Hayashi, Hidetoshi ; Kiura, Katsuyuki ; Satouchi, Miyako ; Sugawara, Shunichi ; Hida, Toyoaki ; Iwamoto, Yasuo ; Inoue, Akira ; Takeda, Koji ; Ikeda, Satoshi ; Nakagawa, Tomoki ; Takeda, Kentaro ; Asahina, Seitaro ; Komatsu, Kanji ; Morita, Satoshi ; Fukuoka, Masahiro ; Nakagawa, Kazuhiko. / ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. In: Cancer Science. 2018 ; Vol. 109, No. 8. pp. 2532-2538.
@article{0673ff7fc0b44823af1e71c74e14d26f,
title = "ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-na{\"i}ve Japanese patients with EGFR mutation-positive non-small-cell lung cancer",
abstract = "Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50{\%} of East Asian patients with non-small-cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitors (TKIs). ASP8273 is an irreversible EGFR-TKI, given orally, that inhibits EGFR activating mutations and has shown clinical activity in patients with EGFR mutation-positive NSCLC. Epidermal growth factor receptor-TKI-na{\"i}ve Japanese adult patients (≥20 years) with NSCLC harboring EGFR mutations were enrolled in this open-label, single-arm, phase II study (ClinicalTrials.gov identifier NCT02500927). Patients received ASP8273 300 mg once daily until discontinuation criteria were met. The primary end-point was to determine the safety of ASP8273 300 mg; the secondary end-point was antitumor activity defined by RECIST version 1.1. Thirty-one patients (12 men and 19 women; median age, 64 years [range, 31-82 years]) with EGFR mutation-positive NSCLC were enrolled; as of 23 February 2016, 25 patients (81{\%}) were still on study. Of the 31 patients, 27 (87{\%}) had an exon 19 deletion (n = 13, 42{\%}) or an L858R (n = 14, 45{\%}) EGFR activating mutation, and two (7{\%}) had an L861Q mutation. Five patients (16{\%}) had other EGFR activating mutations, two had an activating mutation and the T790M resistance mutation. The most commonly reported treatment-emergent adverse event was diarrhea (n = 24, 77{\%}). All patients had at least one post-baseline scan; one patient (3{\%}) achieved a confirmed complete response, 13 (42{\%}) had a confirmed partial response, and 15 (48{\%}) had confirmed stable disease (disease control rate, 94{\%} [n = 29/31]) per investigator assessment. Once-daily ASP8273 at 300 mg was generally well tolerated and showed antitumor activity in TKI-na{\"i}ve Japanese patients with EGFR mutation-positive NSCLC.",
keywords = "clinical trial, epidermal growth factor receptor, non-small-cell carcinoma, signal transduction inhibitors/kinase inhibitor, tyrosine kinase inhibitor",
author = "Koichi Azuma and Makoto Nishio and Hidetoshi Hayashi and Katsuyuki Kiura and Miyako Satouchi and Shunichi Sugawara and Toyoaki Hida and Yasuo Iwamoto and Akira Inoue and Koji Takeda and Satoshi Ikeda and Tomoki Nakagawa and Kentaro Takeda and Seitaro Asahina and Kanji Komatsu and Satoshi Morita and Masahiro Fukuoka and Kazuhiko Nakagawa",
year = "2018",
month = "8",
day = "1",
doi = "10.1111/cas.13651",
language = "English",
volume = "109",
pages = "2532--2538",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer

AU - Azuma, Koichi

AU - Nishio, Makoto

AU - Hayashi, Hidetoshi

AU - Kiura, Katsuyuki

AU - Satouchi, Miyako

AU - Sugawara, Shunichi

AU - Hida, Toyoaki

AU - Iwamoto, Yasuo

AU - Inoue, Akira

AU - Takeda, Koji

AU - Ikeda, Satoshi

AU - Nakagawa, Tomoki

AU - Takeda, Kentaro

AU - Asahina, Seitaro

AU - Komatsu, Kanji

AU - Morita, Satoshi

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of East Asian patients with non-small-cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitors (TKIs). ASP8273 is an irreversible EGFR-TKI, given orally, that inhibits EGFR activating mutations and has shown clinical activity in patients with EGFR mutation-positive NSCLC. Epidermal growth factor receptor-TKI-naïve Japanese adult patients (≥20 years) with NSCLC harboring EGFR mutations were enrolled in this open-label, single-arm, phase II study (ClinicalTrials.gov identifier NCT02500927). Patients received ASP8273 300 mg once daily until discontinuation criteria were met. The primary end-point was to determine the safety of ASP8273 300 mg; the secondary end-point was antitumor activity defined by RECIST version 1.1. Thirty-one patients (12 men and 19 women; median age, 64 years [range, 31-82 years]) with EGFR mutation-positive NSCLC were enrolled; as of 23 February 2016, 25 patients (81%) were still on study. Of the 31 patients, 27 (87%) had an exon 19 deletion (n = 13, 42%) or an L858R (n = 14, 45%) EGFR activating mutation, and two (7%) had an L861Q mutation. Five patients (16%) had other EGFR activating mutations, two had an activating mutation and the T790M resistance mutation. The most commonly reported treatment-emergent adverse event was diarrhea (n = 24, 77%). All patients had at least one post-baseline scan; one patient (3%) achieved a confirmed complete response, 13 (42%) had a confirmed partial response, and 15 (48%) had confirmed stable disease (disease control rate, 94% [n = 29/31]) per investigator assessment. Once-daily ASP8273 at 300 mg was generally well tolerated and showed antitumor activity in TKI-naïve Japanese patients with EGFR mutation-positive NSCLC.

AB - Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of East Asian patients with non-small-cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitors (TKIs). ASP8273 is an irreversible EGFR-TKI, given orally, that inhibits EGFR activating mutations and has shown clinical activity in patients with EGFR mutation-positive NSCLC. Epidermal growth factor receptor-TKI-naïve Japanese adult patients (≥20 years) with NSCLC harboring EGFR mutations were enrolled in this open-label, single-arm, phase II study (ClinicalTrials.gov identifier NCT02500927). Patients received ASP8273 300 mg once daily until discontinuation criteria were met. The primary end-point was to determine the safety of ASP8273 300 mg; the secondary end-point was antitumor activity defined by RECIST version 1.1. Thirty-one patients (12 men and 19 women; median age, 64 years [range, 31-82 years]) with EGFR mutation-positive NSCLC were enrolled; as of 23 February 2016, 25 patients (81%) were still on study. Of the 31 patients, 27 (87%) had an exon 19 deletion (n = 13, 42%) or an L858R (n = 14, 45%) EGFR activating mutation, and two (7%) had an L861Q mutation. Five patients (16%) had other EGFR activating mutations, two had an activating mutation and the T790M resistance mutation. The most commonly reported treatment-emergent adverse event was diarrhea (n = 24, 77%). All patients had at least one post-baseline scan; one patient (3%) achieved a confirmed complete response, 13 (42%) had a confirmed partial response, and 15 (48%) had confirmed stable disease (disease control rate, 94% [n = 29/31]) per investigator assessment. Once-daily ASP8273 at 300 mg was generally well tolerated and showed antitumor activity in TKI-naïve Japanese patients with EGFR mutation-positive NSCLC.

KW - clinical trial

KW - epidermal growth factor receptor

KW - non-small-cell carcinoma

KW - signal transduction inhibitors/kinase inhibitor

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85052493549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052493549&partnerID=8YFLogxK

U2 - 10.1111/cas.13651

DO - 10.1111/cas.13651

M3 - Article

C2 - 29807396

AN - SCOPUS:85052493549

VL - 109

SP - 2532

EP - 2538

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -